Premium
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
Author(s) -
Claudiani Simone,
Apperley Jane F.,
Deplano Simona,
Khorashad Jamshid,
Foroni Letizia,
Palanicawandar Renuka,
Perry Richard,
Milojkovic Dragana
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24495
Subject(s) - nilotinib , medicine , dasatinib , imatinib , rash , adverse effect , imatinib mesylate , tyrosine kinase inhibitor , oncology , myeloid leukemia , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom